Payment overview · 2025
General Payments
$59.34
3 reported records · 2 companies
Healthcare provider profile · identity verified
Thomas E Renfro, MD
Allopathic & Osteopathic Physicians|Internal Medicine · COEBURN, VA · NPI 1497726376
Verified facts
What the public records show
CMS Open Payments records show Thomas E Renfro, MD received $59.34 in general payments during 2025 across 3 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 77.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $45.75 | 77.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.59 | 22.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $59.34 | 3 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $45.75 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.59 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 405 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 356 | 73 |
| Gabapentin | Gabapentin | 341 | 71 |
| Levothyroxine Sodium | Levothyroxine Sodium | 320 | 73 |
| Losartan Potassium | Losartan Potassium | 305 | 78 |
| Potassium Chloride | Potassium Chloride | 278 | 56 |
| Omeprazole | Omeprazole | 256 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 45 |
| Metformin Hcl | Metformin Hcl | 186 | 44 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 31 |
| Metoprolol Succinate | Metoprolol Succinate | 160 | 36 |
| Simvastatin | Simvastatin | 158 | 37 |
| Lisinopril | Lisinopril | 149 | 39 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 146 | 41 |
| Furosemide | Furosemide | 144 | 35 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 142 | 40 |
| Ezetimibe | Ezetimibe | 137 | 36 |
| Eliquis | Apixaban | 135 | 18 |
| Sertraline Hcl | Sertraline Hcl | 124 | 28 |
| Montelukast Sodium | Montelukast Sodium | 123 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 121 | 31 |
| Meloxicam | Meloxicam | 120 | 31 |
| Hydrochlorothiazide | Hydrochlorothiazide | 119 | 29 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 114 | 26 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 107 | 24 |
| Carvedilol | Carvedilol | 104 | 23 |
| Allopurinol | Allopurinol | 102 | 22 |
| Spironolactone | Spironolactone | 101 | 18 |
| Chlorthalidone | Chlorthalidone | 96 | 23 |
| Clonazepam | Clonazepam | 92 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 91 | 20 |
| Tramadol Hcl | Tramadol Hcl | 91 | 21 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 89 | 17 |
| Famotidine | Famotidine | 87 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 85 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 84 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 77 | 12 |
| Alendronate Sodium | Alendronate Sodium | 76 | 16 |
| Candesartan Cilexetil | Candesartan Cilexetil | 73 | 12 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 71 | 20 |
| Glimepiride | Glimepiride | 69 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 60 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 57 | 11 |
| Pregabalin | Pregabalin | 57 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 54 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 54 | 15 |
| Ondansetron Odt | Ondansetron | 51 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | 16 |
| Colestipol Hcl | Colestipol Hcl | 50 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 50 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 49 | 13 |
| Mirtazapine | Mirtazapine | 49 | 14 |
| Clonidine Hcl | Clonidine Hcl | 46 | suppressed |
| Ibuprofen | Ibuprofen | 46 | 11 |
| Ozempic | Semaglutide | 46 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 45 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Finasteride | Finasteride | 43 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 42 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 12 |
| Atenolol | Atenolol | 38 | 11 |
| Donepezil Hcl | Donepezil Hcl | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 37 | suppressed |
| Lorazepam | Lorazepam | 37 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 16 |
| Memantine Hcl | Memantine Hcl | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 35 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 33 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 31 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 30 | suppressed |
| Celecoxib | Celecoxib | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 29 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 29 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Aripiprazole | Aripiprazole | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Repatha Sureclick | Evolocumab | 26 | suppressed |
| Valsartan | Valsartan | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Enbrel Sureclick | Etanercept | 25 | suppressed |
| Lactulose | Lactulose | 25 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 25 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 24 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 24 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 23 | suppressed |
| Nitroglycerin | Nitroglycerin | 23 | 13 |
| Rizatriptan | Rizatriptan Benzoate | 23 | suppressed |
| Prednisone | Prednisone | 22 | 18 |
| Estradiol | Estradiol | 21 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Jardiance | Empagliflozin | 20 | suppressed |
| Ultiguard Safepack-Pen Needle | Pen Needle, Diabetic,disp Unit | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 16 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Advocate Syringes | Syringe And Needle,insulin,1ml | 15 | suppressed |
| Fentanyl | Fentanyl | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 14 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 14 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 13 | suppressed |
| Azithromycin | Azithromycin | 12 | suppressed |
| Cephalexin | Cephalexin | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Lasix | Furosemide | 12 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nyamyc | Nystatin | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Buprenorphine Hcl | Buprenorphine Hcl | 11 | suppressed |
| Eplerenone | Eplerenone | 11 | suppressed |
| Fluorouracil | Fluorouracil | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Novolin R | Insulin Regular, Human | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 11 | suppressed |
| Ulticare | Syringe And Needle,insulin,1ml | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $59.34 · 3 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, FARXIGA | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error